Psyence BioMed unit signs ibogaine license term sheet with PsyLabs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
September 28, 2026 7:00 AM EDTBinding term sheet with PsyLabs provides Psyence BioMeds Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs pharmaceutical-grade ibogaine, subject to a definitive agreement
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (Psyence BioMed or the Company) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), has entered into a binding term sheet with Psyence Labs Ltd. (PsyLabs) under which PsyLabs will grant TIRC an exclusive license, supply and wholesale distribution arrangement for PsyLabs pharmaceutical-grade ibogaine in the United States.... More
